CANCER-EMBRYONIC ANTIGEN IN PREDICTING THERAPEUTIC TUMOR PATHOMORPHISM AFTER NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH RECTAL CANCER

The purpose of the study was to evaluate the prognostic significance of carcinoerembryonic antigen in patients with rectal cancer and correlate its baseline with the degree of therapeutic pathomorphosis after neoadjuvant chemoradiotherapy.

Materials and methods. An estimate of the informative value of carcinoerembryonic antigen (CEA) indices in 179 patients with colorectal cancer determined before and after preoperative chemoradiotherapy (CRT) in SOD 50 Gy.

Results. Analysis of the results presented in the study showed that in all patients, CRT caused a significant decrease in the level of CEA (–71%) 10 weeks after its end (p < 0.001). In the course of the pathomorphological study, after the neoadjuvant treatment, the first degree of tumor pathomorphism was recorded in 4.5% of patients, II – 38.5%, III – 45%, IV – 12% (the degree of pathomorphosis is not related to the clinical stage and the degree of differentiation of colorectal cancer). It was revealed that patients with III and IV degrees of therapeutic pathomorphosis initially had a CEA level lower, in comparison with patients with grade I-II. Clinical progression of the disease is diagnosed in 24% of cases (43/179). It was noted that in patients with the IV degree of therapeutic pathomorphism of the tumor, no recurrence of the rectal cancer was detected in either case.

Conclusion. The results of the study showed that the problem of individual prediction of the effectiveness of combined treatment of the rectal cancer remains very relevant, rather complicated and yet not completely solved. However, it can be assumed that the use of such an indicator as CEA in monitoring patients after the treatment, can serve as a criterion for the sensitivity of colorectal cancer to CRT. Initially low antigen level can be considered as a positive factor of tumor response to ongoing treatment and disease-free survival of patients with locally advanced rectal cancer.

1. The state of cancer care in Russia in 2016. Edited by A.D.Kaprin, V.V.Starinskii, G.V.Petrova. Мoscow, 2017, 236 p. Available at: htt ww.oncology.ru/service/stati ti conditi (In Russian).

2. Cancer Today. M. Ervik, F. Lam, J. Ferlay, L. Mery, I. Soerjomataram, F. Bray. Lyon, France: International Agency for Research on Cancer, 2016. Available from: http://gco.iarc.fr/today https:// doi.org/10.1016/s0140-6736(15)00135-x

3. Campos FG, Calijuri-Hamra MC, Imperiale AR, Kiss DR, Nahas SC, Cecconello I. Locally advanced colorectal cancer: results of surgical treatment and prognostic factors. Arq Gastroenterol. 2011 Oct-Dec;48(4):270-5.

4. Glimelius B. Which rectal cancers are locally advanced? Oncology (Williston Park). 2012 Aug;26(8):743, 746, 751-2.

5. Berdov BA, Erygin DV, Nevolskih AA. Locally advanced and prognostically unfavorable colorectal cancer (definition of concepts and treatment methods). Proceedings of the conference “Modern aspects of the diagnosis and treatment of colorectal cancer”, 2015, p. 36. (In Russian).

6. Erygin DV, Berdov BA, Nevol’skikh AA, Titova LN, Smirnova SG. Neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Onkologiya. Zhurnal imeni P.A. Gerzena (P.A. Herzen Journalof Oncology) 2015;4(1):13-20. DOI: 10.17116/ onkolog20154113-20

7. Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al.; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Aug;16(8):979-89. DOI: 10.1016/S1470-2045(15)00159-X

8. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative Chemoradiotherapy for rectal cancer. J Clin Oncol. 2012 Jun 1;30(16):1926-33. DOI: 10.1200/JCO.2011.40.1836.

9. Lim SB, Choi HS, Jeong SY, Kim DY, Jung KH, Hong YS, et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg. 2008 Aug;248(2):243-51. DOI: 10.1097/SLA.0b013e31817fc2a0.

10. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012 May 20;30(15):1770-6. DOI: 10.1200/JCO.2011.39.7901

11. Dayde D, Tanaka I, Jain R, Tai MC, Taguchi A. Predictive and prognostic molecular biomarkers for response to neoadjuvant chemoradiation in rectal cancer. Int J Mol Sci. 2017 Mar 7;18(3). pii: E573. DOI: 10.3390/ijms18030573.

12. Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014 May 20;32(15):1554-62. doi: 10.1200/JCO.2013.54.3769

13. Nevolskikh AA, Berdov BA, Neborak YuT, Silatyeva NK, Lantsov DS. Lateral resection margin as a prognostic factor in rectal cancer. Siberian Journal of Oncology. 2010;5:5-10. (In Russian).

14. Lim SH, Chua W, Henderson C, Ng W, Shin JS, Chantrill L, et al. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Crit Rev Oncol Hematol. 2015 Oct;96(1):67-80. DOI: 10.1016/j.critrevonc.2015.05.003.

15. Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, Sturgeon C. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014 Jun 1;134(11):2513-22. DOI: 10.1002/ijc.28384.

16. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2018. Fort Washington, PA: NCCN; 2018

17. Becerra AZ, Probst CP, Tejani MA, Aquina CT, González MG, Hensley BJ, et al. Evaluating the prognostic role of elevated preoperative carcinoembryonic antigen levels in colon cancer patients: results from the National Cancer Database. Ann Surg Oncol. 2016 May;23(5):1554-61. DOI: 10.1245/s10434-015-5014-1.

18. Colloca G, Venturino A, Vitucci P. Pre-treatment carcinoembryonic antigen and outcome of patients with rectal cancer receiving neo-adjuvant chemo-radiation and surgical resection: a systematic review and meta-analysis. Med Oncol. 2017 Sep 7;34(10):177. DOI: 10.1007/s12032-017-1037-8.

19. Ryan JE, Warrier SK, Lynch AC, Ramsay RG, Phillips WA, Heriot AG. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2016 Mar;18(3):234-46. DOI: 10.1111/codi.13207.

20. Kim NK, Hur H. New perspectives on predictive biomarkers of tumor response and their clinical application in preoperative chemoradiation therapy for rectal cancer. Yonsei Med J. 2015 Nov;56(6):1461-77. DOI: 10.3349/ymj.2015.56.6.1461

21. Filiz AI, Sucullu I, Kurt Y, Karakas DO, Gulec B, Akin ML. Persistent high postoperative carcinoembryonic antigen in colorectal cancer patients--is it important? Clinics (Sao Paulo). 2009;64(4):287-94.

22. Jeong S, Nam TK, Jeong JU, Kim SH, Kim K, Jang HS, et al. Postoperative carcinoembryonic antigen level has a prognostic value for distant metastasis and survival in rectal cancer patients who receive preoperative chemoradiotherapy and curative surgery: a retrospective multi-institutional analysis. Clin Exp Metastasis. 2016 Dec;33(8):809-816. DOI: 10.1007/s10585-016-9818-6

23. Konishi T, Shimada Y, Hsu M, Tufts L, Jimenez-Rodriguez R, Cercek A, et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 2018 Mar 1;4(3):309-315. DOI: 10.1001/jamaoncol.2017.4420.

24. Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, et al. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013 Dec 10;31(35):4465-70. DOI: 10.1200/JCO.2013.50.7442.

25. Verberne CJ, Zhan Z, van den Heuvel E, Grossmann I, Doornbos PM, Havenga K, et al. Intensified follow-up in colorectal cancer patients using frequent Carcino-Embryonic Antigen (CEA) measurements and CEA-triggered imaging: Results of the randomized “CEAwatch” trial. Eur J Surg Oncol. 2015 Sep;41(9):118896. DOI: 10.1016/j.ejso.2015.06.008.

26. Shinkins B, Primrose JN, Pugh SA, Nicholson BD, Perera R, James T, Mant D. Serum carcinoembryonic antigen trends for diagnosing colorectal cancer recurrence in the FACS randomized clinical trial. Br J Surg. 2018 May;105(6):658-662. DOI: 10.1002/ bjs.10819.

27. Perez RO, São Julião GP, Habr-Gama A, Kiss D, Proscurshim I, Campos FG, et al. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Dis Colon Rectum. 2009 Jun;52(6):113743. doi: 10.1007/DCR.0b013e31819ef76b.

28. Jang NY, Kang SB, Kim DW, Kim JH, Lee KW, Kim IA, Kim JS. The role of carcinoembryonic antigen after neoadjuvant chemoradiotherapy in patients with rectal cancer. Dis Colon Rectum. 2011 Feb;54(2):245-52. DOI: 10.1007/DCR.0b013e3181fcee68.

29. Kim CW, Yu CS, Yang SS, Kim KH, Yoon YS, Yoon SN, et al. Clinical significance of pre-to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. Ann Surg Oncol. 2011 Nov;18(12):3271-7. DOI: 10.1245/s10434-011-1740-1

30. Sung SY, Son SH, Kay CS, Lee YS. Prognosis can be predicted more accurately using pre-and postchemoradiotherapy carcinoembryonic antigen levels compared to only prechemoradiotherapy carcinoembryonic antigen level in locally advanced rectal cancer patients who received neoadjuvant chemoradiotherapy. Medicine (Baltimore). 2016 Mar;95(10):e2965. DOI: 10.1097/MD.0000000000002965.

31. Ryan JE, Warrier SK, Lynch AC, Heriot AG. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2015 Oct;17(10):849-61. DOI: 10.1111/codi.13081

32. Kaprin AD, Galkin VN, Zhavoronkov LP, Ivanov VK, Ivanov SA, Romanko YuS. Synthesis of basic and applied research is the basis of obtaining high-quality findings and translating them into clinical practice. Radiation and Risk. 2017;26(2):26-40. DOI: 10.21870/0131-3878-2017-26-2-26-40

33. Wallin U, Rothenberger D, Lowry A, Luepker R, Mellgren A. CEA—a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer. Dis Colon Rectum. 2013 Jul;56(7):859-68. DOI: 10.1097/DCR.0b013e31828e5a72.

34. Park YA, Lee KY, Kim NK, Baik SH, Sohn SK, Cho CW. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol. 2006 May;13(5):645-50. DOI: 10.1245/ASO.2006.03.090